Core Viewpoint - The competition in the GLP-1 drug market is accelerating with the recent acceptance of the listing application for semaglutide injection by Fosun Wanbang Pharmaceutical, indicating a growing focus on diabetes treatment and weight management in China [4][5]. Industry Evaluation - Semaglutide is a representative product in diabetes treatment and weight management, effectively lowering blood sugar and promoting weight loss while positively impacting cardiovascular risk factors. The demand for prescriptions remains strong, and the market has significant expansion potential [5]. - The core patent for semaglutide is set to expire in March 2026, prompting domestic companies to accelerate their development efforts. Currently, there are nine domestic companies that have submitted listing applications, with at least ten more similar drugs in II/III clinical stages [5][7]. - The listing application by Fosun Wanbang for semaglutide injection follows a 3.3 class registration path for biosimilars, having completed a pivotal III clinical trial. This reflects the differentiated strategies of companies in terms of technical investment and market positioning [7][8]. Company Overview - Fosun Wanbang Pharmaceutical is a key member of Fosun Pharma Group, with established capabilities in gene-engineered drug development and production. The acceptance of their semaglutide injection application marks a significant step in their strategy for diabetes and obesity treatment [8].

Core Viewpoint - The article emphasizes the importance of long-term weight management as part of China's "Healthy China 2030" strategy, highlighting the growing market and innovative solutions in the weight management sector [2][6][9]. Market Overview - The weight management market in China is projected to exceed 326 billion yuan by 2025, indicating a significant growth opportunity for various enterprises [6]. - The National Health Commission has initiated a three-year "Weight Management Year" campaign, aiming to enhance public awareness and skills in weight management, with a target of reducing the annual obesity rate increase by 10% by 2026 [22][26]. Product Innovations - Companies are showcasing a range of innovative products at events like the China International Import Expo, including dietary adjustments, exercise aids, and medical interventions [6]. - Herbal supplement brands are promoting traditional Chinese medicine concepts to help individuals achieve a sustainable healthy weight, focusing on holistic health management [7]. Technological Integration - The integration of technology in weight management is highlighted, with companies like Qiaoshan Technology introducing AI and IoT solutions for personalized fitness plans and health tracking [10]. - Innovative medical interventions, such as the intragastric balloon developed by Boston Scientific, provide new options for severe obesity management, emphasizing minimally invasive procedures [12]. Consumer Trends - There is a growing recognition of the need for comprehensive dietary habits and lifestyle changes rather than short-term dieting, as reflected in the offerings of various health brands [7][9]. - The emphasis on health-conscious products, such as low-glycerol oils for obese individuals, indicates a shift towards healthier consumer choices in the food industry [9].

以下文章来源于肥胖世界ObesityWorld ，作者欢迎订阅 肥胖世界ObesityWorld . 《肥胖世界》Obesity World - 同步传真肥胖及代谢国际新学术进展，为医学减重临床、教研人员搭建一座与国际接轨的桥梁，「每医健」旗下内容平台。 2025年11月4日至7日，备受关注的美国肥胖周（ObesityWeek 2025）在美国亚特兰大隆重举行。作为全球肥胖研究与治疗领域极具影响力的 国际盛会，肥胖周汇聚了世界各地的权威专家、学者及业界领袖，共同探讨肥胖治疗的最新进展与创新突破。今年大会主题涵盖基础研究到临 床应用等多个方面，其中一项关于"大众减重信息搜索行为"的研究格外引人注目。 这项名为《时机至关重要：减重搜索行为的季节性趋势》的研究，利用18年谷歌趋势数据，揭示了减重搜索行为的独特季节规律。数据显示， 关于生活方式减重的搜索热度每年1月达到峰值，而药物减重相关内容的搜索则在春季（3至4月）迎来高峰。 研究指出，人们在新年伊始更倾向于通过调整生活方式来减重，而春季则更关注药物减重，可能与前期减重效果有限或季节性动力增强有关。 这一发现为公共卫生干预和减重措施的时机选择提供了重要参考——新年 ...

Core Insights - Tirzepatide has shown significant weight loss results, with patients losing an average of 29.2 kg over 84 weeks [2][8] - The drug activates GIP and GLP-1 receptors, leading to reduced caloric intake, appetite regulation, and improved fat metabolism [2] Study Results - The SURMOUNT-3 study demonstrated that patients treated with tirzepatide lost an average of 21.1% of their body weight after 72 weeks, and 26.6% (29.2 kg) after 84 weeks, compared to only 3.8% (4.1 kg) in the placebo group [8] - In the SURMOUNT-CN study, after 52 weeks, the 10 mg and 15 mg groups had weight reductions of 14.4% and 19.9%, respectively, significantly outperforming the placebo group [9] Safety Profile - The overall safety profile of tirzepatide in recent studies is consistent with previous research, with gastrointestinal issues being the most common side effects, mostly mild to moderate [10] Comparison with Surgical Options - Tirzepatide's weight loss efficacy is comparable to that of bariatric surgery, which has an average weight loss rate of 25.2% after one year [11]

Core Viewpoint - The article discusses the recent developments regarding the dual agonist Tirzepatide, highlighting its approval for new indications in China, which expands its market potential in the treatment of type 2 diabetes and obesity [2][4][8]. Group 1: Product Approval and Indications - Tirzepatide, developed by Eli Lilly, is a dual agonist of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) [3][5]. - The drug was approved in the U.S. in May 2022 for the treatment of type 2 diabetes and received its first approval in China in May 2024 for adult patients with inadequate blood sugar control on diet and exercise, along with metformin and/or sulfonylureas [4][5]. - In July 2024, Tirzepatide was approved in China for long-term weight management in adults with obesity (BMI ≥ 28 kg/m²) or overweight (BMI ≥ 24 kg/m² with at least one weight-related comorbidity) [4][5]. Group 2: Market Implications - The approval of Tirzepatide strengthens Eli Lilly's position in the metabolic disease treatment landscape in China, where there is a large population of patients with obesity and type 2 diabetes, providing significant market opportunities [8]. - As the first GIP/GLP-1 dual agonist, Tirzepatide offers treatment options in both blood sugar control and weight management, which is expected to have a substantial impact on the market [8]. - The expansion of Tirzepatide's indications is a key strategic move for Eli Lilly, particularly in the obesity and metabolic disease sectors, potentially solidifying its market position in diabetes treatment and increasing its relevance in weight management [8].

Core Viewpoint - The successful development and market launch of oral semaglutide, a GLP-1 receptor agonist, represents a significant breakthrough in overcoming the challenges associated with oral administration of peptide drugs, enhancing patient compliance and treatment options [5][9]. Group 1: Development and Mechanism - Oral semaglutide has overcome multiple barriers, including instability due to gastric acid and digestive enzymes, large molecular size affecting absorption, and individual variability in efficacy [5][7]. - The use of SNAC (sodium N-[8-(2-hydroxybenzoyl) amino] caprylate) has been pivotal in enhancing the solubility and absorption of semaglutide, while also protecting it from degradation [7][9]. - Pharmacokinetic and pharmacodynamic studies have established optimal dosing methods, ensuring that the semaglutide tablet combined with 300 mg of SNAC achieves maximum bioavailability [7][9]. Group 2: Clinical Efficacy - Clinical studies have demonstrated that a 14 mg dose of oral semaglutide can significantly reduce HbA1c levels by approximately 2% and promote weight loss [9]. - In the OASIS 1 study, participants with obesity or overweight conditions experienced an average weight reduction of 17.4% (18.34 kg) with a 50 mg dose of oral semaglutide, indicating a more pronounced weight loss effect compared to previous studies [9]. Group 3: Mechanism of Action - Semaglutide acts as a "satiety manager" by directly suppressing appetite through central nervous system pathways, slowing gastric emptying, and stabilizing blood sugar levels, which collectively reduce food intake [10][12]. - The drug activates GLP-1 receptors in the hypothalamus and brainstem, enhancing satiety signals while inhibiting hunger signals [10][13]. - It also smooths blood sugar fluctuations by promoting insulin secretion and suppressing glucagon release, thereby reducing cravings for high-calorie foods [12][13].

Core Viewpoint - The article emphasizes the urgent need for a comprehensive approach to weight management in China, highlighting the alarming obesity rates and the associated health risks, while advocating for a multi-faceted strategy that combines policy, technology, and community engagement to combat the obesity crisis [5][7][30]. Group 1: Obesity Crisis and Health Risks - By 2025, the overweight rate among Chinese adults is projected to reach 34.3%, with obesity rates at 16.4%, and a 12-fold increase in youth obesity over the past 15 years [5]. - If no effective measures are taken, by 2030, adult overweight and obesity rates could soar to 70.5%, with youth rates reaching 31.8% [5]. - Obesity is linked to over 200 diseases, leading to annual medical expenditures exceeding 240 billion yuan, with chronic diseases like diabetes and cardiovascular issues on the rise [7]. Group 2: Comprehensive Health Ecosystem Development - The National Health Commission's "National Fitness Plan" promotes a dual focus on muscle gain and fat loss, moving away from the sole reliance on BMI for health assessments [8]. - Innovative products, such as a patented CLA+ whey protein complex, have shown promising results in trials, with users averaging a muscle gain of 2.3 kg and fat loss of 4.7 kg over three months [9]. - The "smart fat-burning machine" initiative aims to enhance metabolic health through wearable devices that monitor blood sugar and mitochondrial activity, with a reported increase in basal metabolic rate by 12%-15% from specific dietary supplements [10]. Group 3: New Frontiers in Weight Management - Community health initiatives in regions like Guangdong and Zhejiang are incorporating gut microbiome testing into routine health checks, providing personalized prebiotic prescriptions for obesity linked to microbiome imbalances [11]. - The integration of skin and fat management post-weight loss is emphasized, with guidelines recommending the inclusion of collagen and elastin in weight loss products, achieving a 91% satisfaction rate in skin recovery post-procedure [12]. - Advanced technologies, such as microencapsulated hyaluronic acid, are being utilized to prevent skin laxity during weight loss [13]. Group 4: Policy, Technology, and Individual Engagement - The establishment of the "Metabolic Cloud Brain" platform aims to provide personalized recommendations for muscle gain, fat loss, and microbiome regulation through a simple scan [14]. - The "15-minute scientific weight loss circle" initiative in Beijing promotes community-based health services, including fitness centers and health stations, to create a supportive environment for weight management [15]. Group 5: Challenges in the Weight Loss Industry - The weight loss market is plagued by misinformation, with 40% of products exaggerating their effectiveness, leading to consumer confusion and potential health risks [17]. - There is a significant gap in obesity treatment resources, with less than 15% of primary hospitals providing obesity management services, and a shortage of specialized weight loss surgeons [18]. Group 6: Future Outlook on Weight Management - The future of weight management is expected to leverage technologies like AR body fat scanning and AI-driven personalized plans, fostering a collaborative environment among government, businesses, and communities [22]. - The narrative of weight loss is shifting from mere calorie restriction to a more nuanced approach that balances muscle and fat management, gut health, and hormonal regulation, aiming for a holistic improvement in public health [23].

Core Viewpoint - The article discusses the importance of basal metabolic rate (BMR) in weight management and how increasing BMR can facilitate weight loss without altering diet or exercise routines [8][11]. Summary by Sections Understanding Basal Metabolic Rate (BMR) - BMR accounts for approximately 45% to 70% of daily energy expenditure, essential for maintaining vital functions like heartbeat and respiration [8]. - The article provides an example comparing two individuals with different BMRs, illustrating how a higher BMR leads to greater daily calorie expenditure [8][12]. Measuring BMR - The most accurate method for measuring BMR is the "direct calorimetry" method, which is impractical for everyday use. Common methods like body fat scales provide estimates with significant error margins [9]. - Two formulas for estimating BMR are provided, one based on weight and gender, and another from the National Health Commission's guidelines [9]. Factors Influencing BMR - BMR is influenced by factors such as height, age, gender, genetics, hormones, and body composition. While some factors cannot be changed, muscle mass can be increased to enhance BMR [14]. Strategies to Increase BMR 1. **Scientific Exercise**: Engaging in resistance training can increase muscle mass, thereby boosting BMR. A combination of aerobic and resistance training can enhance BMR by 8% to 15% [15]. 2. **High-Quality Protein Intake**: Consuming adequate protein helps maintain muscle mass during weight loss, preventing a decrease in BMR [17]. 3. **Balanced Diet**: Avoiding extreme dieting is crucial, as it can lower BMR. A balanced intake of carbohydrates, proteins, and fats is recommended [18]. 4. **Proper Hydration**: Staying hydrated aids in weight loss and metabolic processes, with a recommendation of 2000 milliliters of water daily [20]. Conclusion - Increasing BMR can support weight loss efforts, but it must be combined with a balanced diet and regular exercise to be effective [20].

Core Viewpoint - The 2025 list of prohibited substances has been officially released, including 400 types of drugs, with 9 new additions compared to 2024 [2] Group 1: New Additions to the Prohibited List - Anabolic agents: 95 types (no new additions) [3] - Peptide hormones: 75 types (2 new additions) [3] - Narcotic drugs: 14 types (no new additions) [3] - Stimulants (including psychoactive drugs): 84 types (2 new additions) [3] - Precursor chemicals: 3 types (no new additions) [3] - Medical toxic drugs: 1 type (no new additions) [4] - Other drugs: 128 types (5 new additions) [4] Group 2: Specific New Drugs - The 2 new peptide hormones are: - S519 (No. 159) [6] - S597 (No. 160) [6] - The 2 new stimulants are: - Midodrine (No. 241) [7] - Tisofenacin (No. 265) [7] - The 5 new drugs in the "Other" category are: - Elagolix (No. 323) [7] - MOTS-c (No. 351) [7] - S-107 (No. 375) [7] - S48168 (No. 376) [7] - Hipamine (No. 400) [7] Group 3: Clarification on Semaglutide - Recent claims that Semaglutide is a stimulant are inaccurate, as it is not listed in the 2025 directory [7] - Semaglutide is classified under GLP-1 receptor agonists, which are not included in the 2025 directory [8] - The only related substance in the directory is IGF-1 (Insulin-like Growth Factor 1), which is different from GLP-1 [8] - Semaglutide remains under monitoring programs to observe its impact on athletes, consistent with 2024 arrangements [8]

Core Viewpoint - The article discusses the importance of basal metabolic rate (BMR) in weight management and how increasing BMR can facilitate weight loss without altering diet or exercise routines [8][11]. Summary by Sections Understanding Basal Metabolic Rate - Basal metabolic rate (BMR) accounts for approximately 45% to 70% of daily energy expenditure, essential for maintaining vital functions like heartbeat and respiration [8]. - BMR can be influenced by factors such as height, age, gender, genetics, and muscle mass, with muscle mass being a key area for improvement [14]. Measuring Basal Metabolic Rate - The most accurate method for measuring BMR is direct calorimetry, but it is impractical for everyday use. Common methods include using body fat scales or gym equipment, which provide estimates based on height and weight [9]. - A simple formula for estimating BMR is provided, which varies slightly based on gender and can yield results with a margin of error of 5% to 10% [9][10]. Importance of BMR in Weight Management - Understanding one's BMR can help in planning diets and identifying weight loss plateaus, as a low BMR may hinder weight loss efforts [10]. - Higher BMR leads to greater energy expenditure, making it easier to lose weight under similar dietary and exercise conditions [11][12]. Strategies to Increase Basal Metabolic Rate 1. **Scientific Exercise**: Engaging in resistance training can increase muscle mass, thereby boosting BMR. A combination of aerobic and resistance training can enhance BMR by 8% to 15% [15]. 2. **High-Quality Protein Intake**: Consuming adequate protein helps maintain muscle mass during weight loss, which is crucial for sustaining a higher BMR [17]. 3. **Balanced Diet**: Avoiding extreme dieting is essential, as it can lower BMR. A balanced intake of carbohydrates, proteins, and fats is recommended [18]. 4. **Proper Hydration**: Staying hydrated can aid in weight loss and improve metabolic functions, with a recommendation of 2000 milliliters of water daily [20]. Conclusion - Increasing BMR can significantly aid in weight loss, but it must be coupled with a reasonable diet and regular exercise to be effective [20].